Publications and Presentations

Filter By:

Ipatasertib

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues

Y. Yan, et al.

ARRY-380

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

ARRY-380, a Selective HER2 Inhibitor: From Drug Design to Clinical Evaluation

S. L. Moulder, et al.

Binimetinib

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

A Phase 1 Dose-Escalation Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Advanced Solid Tumors

J. Bendell, et al.

Filanesib

10/18/2011

International Society for the Study of Xenobiotics Conference

An Effective Screening Approach to Assess the Impact of alpha-1 Acid Glycoprotein Binding on the Fraction Unbound of a Drug

K. D. Brown

GDC-0575

07/01/2011

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo

K. D. Davies, et al.

ARRY-502

06/26/2011

World Congress on Inflammation

Potent, Selective, and Orally Active CRTh2 Antagonists for Allergic Disease

L. Burgess, et al.

Ipatasertib

06/07/2011

Cambridge Healthtech Institute Next Generation Kinase Inhibitors

Discovery of GDC-0068: A Selective ATP-competitive Akt Inhibitor for the Treatment of Human Tumors

J. F. Blake, et al.

GDC-0575

04/05/2011

American Association for Cancer Research Annual Meeting

Chk1 inhibition and Wee1 inhibition combine synergistically to inhibit cellular proliferation

K. D. Davies, et al.

Filanesib

04/04/2011

American Association for Cancer Research Annual Meeting

Combination of the KSP Inhibitor ARRY-520 with Bortezomib Causes Sustained Tumor Regressions and Significantly Increased Time to Regrowth in Bortezomib Sensitive and Resistant Models of Multiple Myeloma

R. Woessner, et al.

ARRY-380

04/03/2011

American Association for Cancer Research Annual Meeting

ARRY-380: A Selective, Oral HER2 Inhibitor for the Treatment of Solid Tumors

K. Koch Ph.D.